Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Mario Javier Pineda"'
Autor:
Daniela Matei, Bin Zhang, Masha Kocherginsky, Kaitlyn L. O'Shea, Jeanne Schilder, Deanna Teoh, Emily K. Hill, Sharon E. Robertson, Mario Javier Pineda, Siqi Chen, Emma L. Barber
Supplementary Table 1. Treatment discontinuation due to AE. Supplementary Table 2. Worst grade toxicity related to pembrolizumab in >=5% of patients. Supplementary Table 3. PDL1 staining by objective responder status. Supplementary Figure S1. CONSORT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::056152b593ffee95bb276b11752efb1f
https://doi.org/10.1158/2767-9764.22545096.v1
https://doi.org/10.1158/2767-9764.22545096.v1
Autor:
Daniela Matei, Bin Zhang, Masha Kocherginsky, Kaitlyn L. O'Shea, Jeanne Schilder, Deanna Teoh, Emily K. Hill, Sharon E. Robertson, Mario Javier Pineda, Siqi Chen, Emma L. Barber
Purpose:The objective of this study was to assess the efficacy and safety of pembrolizumab in combination with standard carboplatin/paclitaxel in patients with advanced endometrial cancer.Patients and Methods:This single-arm, open-label, multicenter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::403877e436a48db193327cc61eb7ed7e
https://doi.org/10.1158/2767-9764.c.6550851
https://doi.org/10.1158/2767-9764.c.6550851
Autor:
Emma L. Barber, Siqi Chen, Mario Javier Pineda, Sharon E. Robertson, Emily K. Hill, Deanna Teoh, Jeanne Schilder, Kaitlyn L. O'Shea, Masha Kocherginsky, Bin Zhang, Daniela Matei
Publikováno v:
Cancer Res Commun
Purpose: The objective of this study was to assess the efficacy and safety of pembrolizumab in combination with standard carboplatin/paclitaxel in patients with advanced endometrial cancer. Patients and Methods: This single-arm, open-label, multicent
Autor:
Germana Tognon, Michel Fabbro, Ursula A. Matulonis, Kathleen N. Moore, Susana Banerjee, Mansoor Raza Mirza, Philippe Follana, Kristina Hellman, Philipp Harter, Ronnie Shapira-Frommer, Sven Mahner, Isabel Bover, Sebastien Hazard, Mario Javier Pineda, Diane Provencher, Isabel Palacio Vázquez, Robert M. Wenham, Anne Dørum, Frédéric Goffin, Anna V. Tinker
Publikováno v:
Gynecologic Oncology
Gynecologic Oncology, Elsevier, 2019, 152, pp.560-567. ⟨10.1016/j.ygyno.2018.12.009⟩
Gynecologic Oncology, Elsevier, 2019, 152, pp.560-567. ⟨10.1016/j.ygyno.2018.12.009⟩
Objective. To analyze the safety and efficacy of niraparib in patients aged >= 70 years with recurrent ovarian cancer in the ENGOT-OV16/NOVA trial. Methods. The trial enrolled 2 independent cohorts with histologically diagnosed recurrent ovarian, fal
Autor:
Valery Adorno-Cruz, Mathew Cowan, John R. Lurain, Masha Kocherginsky, Wendy M. Swetzig, Kaitlyn O'Shea, Emily Berry, Shohreh Shahabi, Deanna Taiym, Daniela Matei, Mario Javier Pineda, Valerie Nelson, Nikki L. Neubauer
Publikováno v:
Gynecologic oncology. 163(1)
Objective Tivozanib is a potent selective pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor with a long half-life. This study assessed its activity in patients with recurrent, platinum-resistant ovarian, fallopian tube or prim
Autor:
Steven W. Remmenga, Theresa L. Werner, Richard T. Penson, Lee-may Chen, David M. Gershenson, Ronald D. Alvarez, Sanja Percac-Lima, Peter G. Rose, Lainie P. Martin, Kian Behbakht, Oliver Dorigo, Joseph T. Santoso, Ardeshir Hakam, Mario Javier Pineda, Robert J. Morgan, Miranda Hughes, Paul Sabbatini, Elena Ratner, Laura J. Havrilesky, Jennifer L. Burns, Ursula A. Matulonis, Deborah K. Armstrong, Larry J. Copeland, Carolyn Johnston, Shashikant Lele, Marta A. Crispens, Steven C. Plaxe, Maria De Rosa, David M. O'Malley, Heidi J. Gray, Jamie N. Bakkum-Gamez, Matthew A. Powell
Publikováno v:
Journal of the National Comprehensive Cancer Network. 14:1134-1163
This selection from the NCCN Guidelines for Ovarian Cancer focuses on the less common ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and current algorithms were revised for the 2016 update. The new LCOHs algorithms incl
Autor:
Nicoletta Colombo, Ursula A. Matulonis, Antonio González-Martín, Mansoor Raza Mirza, W. Guo, Prafull Ghatage, Andrés Redondo, Radoslaw Madry, Sven Mahner, Mario Javier Pineda, Sebastien Hazard, Alexander Reinthaller, O. Rosengarten, Jonathan S. Berek, Dominique Berton-Rigaud, Jonathan A. Ledermann, U. Peen, Jalid Sehouli, Susan Ellard, A. Lesoin, Ignace Vergote
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 30(5)
Background: Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved in the United States and Europe for maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in co
Publikováno v:
Gynecologic Oncology Research and Practice
Gynecologic Oncology Research and Practice, Vol 5, Iss 1, Pp 1-9 (2018)
Gynecologic Oncology Research and Practice, Vol 5, Iss 1, Pp 1-9 (2018)
Background Ovarian cancer remains a major health problem for women as it is often diagnosed at a late stage with metastatic disease. There are limited therapeutic agents and survival rates remain poor. The perinucleolar compartment (PNC) has been sho
Autor:
John R. Lurain, Mario Javier Pineda
Publikováno v:
The American Cancer Society's Oncology in Practice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efd44367eea9fdc10d152ea3a6ea7d6c
https://doi.org/10.1002/9781118592168.ch20
https://doi.org/10.1002/9781118592168.ch20
Autor:
Mario Javier Pineda, Kristen J. Vogel Postula, Scott M. Weissman, Shelly M. Weiss, Kathryn M. Buchtel, Carmen Williams
Publikováno v:
Journal of genetic counseling. 27(1)
In December 2014, the FDA approved olaparib, a poly(ADP-ribose) polymerase inhibitor (PARPi) for ovarian cancer patients who have failed three or more lines of chemotherapy and have a germline BRCA1/2 mutation identified through a companion diagnosti